Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Finds IDM Pharma’s Junovan Study Lacking

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Oncologic Drugs Advisory Committee meets May 9 to review the osteosarcoma therapy.

You may also be interested in...



Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18

Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.

Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.

Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel